Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552180 | 0.70 | TAAR1 (0.40) | DRD2HTR1DTAAR1 | |
| SCHEMBL6794127 | 0.64 | PNMT (0.40) | DRD2HTR1DSLC6A4TAAR1 | |
| SCHEMBL6810914 | 0.62 | DRD1 (0.41) | DRD2HTR1DSLC6A4 | |
| SCHEMBL6551697 | 0.61 | TAAR1 (0.72) | DRD2TAAR1 | |
| SCHEMBL7482154 | 0.60 | ADORA1 (0.37) | — | |
| SCHEMBL6812048 | 0.59 | HTR1D (0.56) | DRD2HTR1DSLC6A4 | |
| SCHEMBL5093578 | 0.59 | HTR1D (0.56) | DRD2HTR1DSLC6A4 | |
| SCHEMBL6811406 | 0.58 | HTR1D (0.39) | DRD2HTR1DSLC6A4 | |
| SCHEMBL20906645 | 0.57 | ALDH1A1 (0.52) | DRD2ADRA1DHTR1DADRA1AADRA1B | |
| SCHEMBL6640390 | 0.57 | ALDH1A1 (0.52) | DRD2ADRA1DHTR1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | DRD2 70/4885ADRA1D 28/4885HTR1D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.